Evidence map›Paper›PMID 41184416›Full record

ArticleScientific reports2025

Increased autoantibodies against incretin indicate poor prognosis in patients with diabetes.

Minoru Takemoto, Bo-Shi Zhang, Aiko Hayashi, Hiroki Yamagata, Yoich Yoshida, Masaya Koshizaka, Shunichiro Onishi, Masaya Yamaga, Tomohiko Yoshida, Takahide Hashimoto and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Minoru Takemoto *Department of Diabetes, Metabolism and Endocrinology, School of Medicine, International University of Health and Welfare, 4-3, Kozunomori, Narita, Chiba, 286-8686, Japan. minoru.takemoto@iuhw.ac.jp.
Bo-Shi Zhang *Department of Neurological Surgery, Graduate School of Medicine, Chiba University, 1-8-1 Inohaba, Chuo-ku, Chiba, 260-8670, Japan.
Aiko Hayashi *Department of Endocrinology, Hematology, and Gerontology, Chiba University Graduate School of Medicine, 1-8-1 Inohaba, Chuo-ku, Chiba, 260-8670, Japan.
Hiroki Yamagata *Department of Diabetes and Endocrinology, Japanese Red Cross Asahikawa Hospital, 1 Chome-1-1 Akebono 1 Jo, Asahikawa, Hokkaido, Japan.
Yoich YoshidaDepartment of Neurological Surgery, Graduate School of Medicine, Chiba University, 1-8-1 Inohaba, Chuo-ku, Chiba, 260-8670, Japan.
Masaya KoshizakaCenter for Preventive Medical Sciences, Chiba University, 1-8-1 Inohaba, Chuo-ku, Chiba, 260-8670, Japan.
Shunichiro OnishiDepartment of Diabetes, Metabolism and Endocrinology, School of Medicine, International University of Health and Welfare, 4-3, Kozunomori, Narita, Chiba, 286-8686, Japan.
Masaya YamagaDepartment of Diabetes, Metabolism and Endocrinology, School of Medicine, International University of Health and Welfare, 4-3, Kozunomori, Narita, Chiba, 286-8686, Japan.
Tomohiko YoshidaCenter for Preventive Medical Sciences, Chiba University, 1-8-1 Inohaba, Chuo-ku, Chiba, 260-8670, Japan.
Takahide HashimotoCenter for Preventive Medical Sciences, Chiba University, 1-8-1 Inohaba, Chuo-ku, Chiba, 260-8670, Japan.
Naoki OhtakeDepartment of Diabetes, Metabolism and Endocrinology, School of Medicine, International University of Health and Welfare, 4-3, Kozunomori, Narita, Chiba, 286-8686, Japan.
Takahiro IshikawaEastern Chiba Medical Center, 6-2, 3 Cho-me, Okayamadai, Tougane-shi, Chiba, 283-8686, Japan.
Hirotaka TakizawaPort Square Kashiwado Clinic, Kashiwado Memorial Foundation, 1-35, Tonya-cho, Chuo-ku, Chiba, 260-0025, Japan.
Takaki HiwasaDepartment of Neurological Surgery, Graduate School of Medicine, Chiba University, 1-8-1 Inohaba, Chuo-ku, Chiba, 260-8670, Japan.

Funding

Japan Science and Technology Agency 23K06889, 24K10559
6 · The paper itself

Abstract

This retrospective cohort study aimed to elucidate the clinical significance of measuring autoantibodies against incretins in diabetes. We enrolled 274 patients with diabetes (mean age ± standard deviation [SD]: 63.1 ± 12.1 years) and 109 healthy controls (mean age: 58.0 ± 5.8 years). Titers of autoantibodies against incretins (glucose-dependent insulinotropic peptide and glucagon-like peptide-1) were measured using an amplified luminescent proximity homogeneous assay-linked immunosorbent assay. Both incretin antibody titers were significantly higher in patients with diabetes than in healthy controls (both P < 0.01). A mean 4.9-year (maximum 10-year) follow-up study revealed that patients who tested positive for glucose-dependent insulinotropic peptide antibodies had significantly worse prognoses than those who tested negative (P = 0.0072). Patients who tested positive for glucagon-like peptide-1 antibodies also tended to have worse prognoses (P = 0.06). To the best of our knowledge, this is the first study to investigate autoantibodies against incretin hormones in patients with diabetes. These autoantibodies may serve as novel prognostic biomarkers and provide a rationale for further studies on incretin-based therapies.

Indexed as

AutoantibodiesDiabetes Mellitus, Type 2Gastric Inhibitory PolypeptideGlucagon-Like Peptide 1IncretinsAgedBiomarkersCase-Control StudiesFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesAutoantibodiesBiomarkersGastric Inhibitory PolypeptideGlucagon-Like Peptide 1IncretinsAutoantibodiesGlucagon-like peptide-1Glucose-dependent insulinotropic peptideIncretin

Identifiers

PMID41184416
PMCPMC12583695

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.